Evidence map›Paper›PMID 34841492›Full record

ArticleDrug delivery and translational research2022

Tobramycin-loaded complexes to prevent and disrupt Pseudomonas aeruginosa biofilms.

Delia Boffoli, Federica Bellato, Greta Avancini, Pratik Gurnani, Gokhan Yilmaz, Manuel Romero, Shaun Robertson, Francesca Moret, Federica Sandrelli, Paolo Caliceti and 4 more

Abstract read
PubMed Publisher
In one paragraph

Article in Drug delivery and translational research, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
1.4field-weighted citation impact, top 20% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 17 citations in OpenAlex.

  1. Article
  2. Insights onMicroorganisms · 2024
    Article
  3. FightingInternational journal of molecular sciences · 2023
    Article
  4. Mannosylated Polycations Target CD206Biomacromolecules · 2022
    Article
  5. Tobramycin Nanoantibiotics and Their Advantages: A Minireview.International journal of molecular sciences · 2022
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 2 institutions in 2 countries.

Delia BoffoliDepartment of Pharmaceutical and Pharmacological Sciences, University of Padova, via F. Marzolo 5, 35131, Padova, Italy.
Federica BellatoDepartment of Pharmaceutical and Pharmacological Sciences, University of Padova, via F. Marzolo 5, 35131, Padova, Italy.
Greta AvanciniDepartment of Pharmaceutical and Pharmacological Sciences, University of Padova, via F. Marzolo 5, 35131, Padova, Italy.
Pratik GurnaniDivision of Molecular Therapeutics and Formulation, School of Pharmacy, University of Nottingham, Nottingham, NG7 2RD, UK.
Gokhan YilmazDivision of Molecular Therapeutics and Formulation, School of Pharmacy, University of Nottingham, Nottingham, NG7 2RD, UK.
Manuel Romero
Shaun RobertsonSchool of Life Sciences, Nottingham University Biodiscovery Institute, National Biofilms Innovation Centre, University of Nottingham, Nottingham, NG7 2RD, UK.
Francesca MoretDepartment of Biology, University of Padova, via U. Bassi 58/B, 35131, Padova, Italy.
Federica SandrelliDepartment of Biology, University of Padova, via U. Bassi 58/B, 35131, Padova, Italy.
Paolo CalicetiDepartment of Pharmaceutical and Pharmacological Sciences, University of Padova, via F. Marzolo 5, 35131, Padova, Italy.
Stefano SalmasoDepartment of Pharmaceutical and Pharmacological Sciences, University of Padova, via F. Marzolo 5, 35131, Padova, Italy.
Miguel CámaraSchool of Life Sciences, Nottingham University Biodiscovery Institute, National Biofilms Innovation Centre, University of Nottingham, Nottingham, NG7 2RD, UK.
Giuseppe MantovaniDivision of Molecular Therapeutics and Formulation, School of Pharmacy, University of Nottingham, Nottingham, NG7 2RD, UK. giuseppe.mantovani@nottingham.ac.uk.ORCID http://orcid.org/0000-0002-0837-0351
Francesca MastrottoDepartment of Pharmaceutical and Pharmacological Sciences, University of Padova, via F. Marzolo 5, 35131, Padova, Italy. francesca.mastrotto@unipd.it.ORCID http://orcid.org/0000-0002-2499-5490
University of Padua · ITUniversity of Nottingham · GB

Funding

Biotechnology and Biological Sciences Research Council BB/R012415/1
6 · The paper itself

Abstract

Carbohydrate-based materials are increasingly investigated for a range of applications spanning from healthcare to advanced functional materials. Synthetic glycopolymers are particularly attractive as they possess low toxicity and immunogenicity and can be used as multivalent ligands to target sugar-binding proteins (lectins). Here, we utilised RAFT polymerisation to synthesize two families of novel diblock copolymers consisting of a glycopolymers block containing either mannopyranose or galactopyranose pendant units, which was elongated with sodium 2-acrylamido-2-methyl-1-propanesulfonate (AMPS) to generate a polyanionic block. The latter enabled complexation of cationic aminoglycoside antibiotic tobramycin through electrostatic interactions (loading efficiency in the 0.5-6.3 wt% range, depending on the copolymer). The resulting drug vectors were characterized by dynamic light scattering, zeta-potential, and transmission electron microscopy. Tobramycin-loaded complexes were tested for their ability to prevent clustering or disrupt biofilm of the Pseudomonas aeruginosa Gram-negative bacterium responsible for a large proportion of nosocomial infection, especially in immunocompromised patients. P. aeruginosa possesses two specific tetrameric carbohydrate-binding adhesins, LecA (PA-IL, galactose/N-acetyl-D-galactosamine-binding) and LecB (PA-IIL, fucose/mannose-binding), and the cell-associated and extracellular adhesin CdrA (Psl/mannose-binding) thus ideally suited for targeted drug delivery using sugar-decorated tobramycin-loaded complexes here developed. Both aliphatic and aromatic linkers were utilised to link the sugar pendant units to the polyacrylamide polymer backbone to assess the effect of the nature of such linkers on bactericidal/bacteriostatic properties of the complexes. Results showed that tobramycin-loaded complexes efficiently suppressed (40 to 60% of inhibition) in vitro biofilm formation in PAO1-L P. aeruginosa and that preferential targeting of PAO1-L biofilm can be achieved using mannosylated glycopolymer-b-AMPS

Indexed as

Pseudomonas aeruginosaTobramycinAnti-Bacterial AgentsBiofilmsHumansMannoseAnti-Bacterial AgentsMannoseTobramycinBiofilmComplexesLectinsPseudomonas aeruginosaSynthetic glycopolymersTobramycin

Identifiers

PMID34841492
OpenAlexW3216480155

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.